VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues, according to a recent BioMedWire release. At the center of its strategy is the proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, which uses two complementary molecules designed to activate cancer-killing activity only when both recognize targets on the same tumor cell. This dual-targeting approach could offer a new level of precision in cancer treatment, addressing a key challenge in oncology: how to destroy cancer cells while sparing healthy ones.
The company is applying this approach to antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), with a particular focus on solid tumors. VERAXA reported promising preclinical findings for its lead BiTAC-TCE program, including selective targeting of cells expressing both intended targets and improved safety alongside comparable efficacy to a conventional TCE in animal studies. These results suggest that the BiTAC platform may reduce off-tumor toxicity, a common limitation of existing TCE therapies, while maintaining potency. If the preclinical findings translate to human trials, VERAXA’s technology could become a valuable addition to the oncology toolbox, potentially improving patient outcomes and expanding treatment options for solid tumors.
VERAXA is also developing complementary ADC technologies, including site-specific conjugation and tumor-selective payload-linker systems, in markets experiencing substantial projected growth. The global ADC market is expected to expand significantly in the coming years, driven by the need for more targeted cancer therapies. By advancing both TCE and ADC platforms, VERAXA aims to position itself in these high-growth segments. The company’s focus on precision oncology aligns with broader industry trends toward therapies that offer better efficacy and safety profiles.
For regular updates about VERAXA Biotech, visit https://investors.veraxa.com. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. To view the full article, visit https://ibn.fm/nHYLn.
About BioMedWire: BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
